Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy

About 3% of all cancer patients suffer from carcinoma of unknown primary site (CUP). In spite of its rarity, we will encounter them. While CUPs manifest a wide variety of clinical presentations, they have often resulted in poor prognosis. Although platinum/taxane combination chemotherapy, e.g. carbo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasui, Hirotoshi, Sato, Kazuhide, Takeyama, Yoshihiro, Kato, Toshio, Hashimoto, Hiroyuki, Fukui, Yasutaka, Yoshihisa, Nagashima, Maeda, Matsuyoshi, Gonda, Hideo, Suzuki, Ryujiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Published online: August, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178322/
https://www.ncbi.nlm.nih.gov/pubmed/25298764
http://dx.doi.org/10.1159/000366268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178322/
https://www.ncbi.nlm.nih.gov/pubmed/25298764
http://dx.doi.org/10.1159/000366268

Ejemplares similares